1. Agios Stock Rises on FDA Accelerated Approval Push for Pyrukynd Label Expansion
Agios Pharmaceuticals saw its stock price climb following the announcement of its intent to seek an accelerated approval pathway from the U.S. Food and Drug Administration (FDA) for a label expansion of its drug, Pyrukynd. This move signals a strategic acceleration of the drug's commercial potential beyond its current ...